Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohortsopen access
- Authors
- Yi, Jun Ho; Jeong, Seong Hyun; Kim, Seok Jin; Yoon, Dok Hyun; Kang, Hye Jin; Koh, Youngil; Kim, Jin Seok; Lee, Won-Sik; Yang, Deok-Hwan; Do, Young Rok; Kim, Min Kyoung; Yoo, Kwai Han; Choi, Yoon Seok; Yun, Whan Jung; Park, Yong; Jo, Jae-Cheol; Eom, Hyeon-Seok; Kwak, Jae -Yong; Shin, Ho-Jin; Park, Byeong Bae; Yi, Seong Yoon; Kwon, Ji-Hyun; Oh, Sung Yong; Kim, Hyo Jung; Sohn, Byeong Seok; Won, Jong Ho; Hong, Dae-Sik; Lee, Ho-Sup; Lee, Gyeong-Won; Suh, Cheolwon; Kim, Won Seog
- Issue Date
- Jan-2023
- Publisher
- 대한암학회
- Keywords
- Diffuse large B-cell lymphoma; Refractory; Clinical outcomes
- Citation
- Cancer Research and Treatment, v.55, no.1, pp.325 - 333
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Cancer Research and Treatment
- Volume
- 55
- Number
- 1
- Start Page
- 325
- End Page
- 333
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191643
- DOI
- 10.4143/crt.2022.008
- ISSN
- 1598-2998
- Abstract
- Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.Materials and Methods We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.Results Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).Conclusion In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.